cGMP-dependent 3',5'-cyclic phosphodiesterase (PDE2A)

cGMP-dependent 3',5'-cyclic phosphodiesterase (PDE2A) is a membrane-bound homodimeric enzyme that hydrolyzes both cAMP and cGMP, thereby regulating the amplitude and duration of cyclic nucleotide signaling in various tissues[1][7]. It contains regulatory GAF domains that bind cGMP, enabling cross-talk between cAMP and cGMP pathways[2][4]. PDE2A plays a key role in neuronal signaling, cardiovascular regulation, and adrenal hormone production[7]. Selective PDE2A inhibitors are under investigation for neuropsychiatric and cardiovascular indications, but no such drugs are yet approved for clinical use[8]. PDE2A is encoded by the PDE2A gene on human chromosome 11 and is part of the larger phosphodiesterase enzyme superfamily[5].

Other names

PDE2ACGS-PDEPDE2A1cGSPDEphosphodiesterase 2AIDDPADScGMP-stimulated cyclic AMP phosphodiesteraseCGS-PDE[1][5]

Inhibition increases intracellular cAMP and cGMP signaling, amplifying these pathways. Modulators affect cell signaling involved in memory, mood, and cardiovascular homeostasis[7][8]